QCG
EIDX

Quadrant Capital Group’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Quadrant Capital Group’s Portfolio EIDX Stock Details EIDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-8
Closed -$1K – 2507
2020
Q4 		$1K Buy
+8
New +$707 ﹤0.01% 2270

Quadrant Capital Group's EIDX Position: Q1 2021 in Review

Quadrant Capital Group sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q1 2021, closing a stake of 8 shares — an estimated $1K sold.

Quadrant Capital Group first reported a position in EIDX in Q4 2020 and held it in 1 quarter. The position peaked at $1K in Q4 2020. 0 funds tracked by Wall St. Rank hold EIDX as of Q1 2021.

  • Quadrant Capital Group reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Quadrant Capital Group sold 8 Eidos Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $1K.
  • Quadrant Capital Group first reported a position in Eidos Therapeutics, Inc. Common Stock in Q4 2020 and held it in 1 quarter.
  • Quadrant Capital Group's Eidos Therapeutics, Inc. Common Stock position peaked at $1K in Q4 2020.
  • 0 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Quadrant Capital Group's 13F filing for Q1 2021, filed 12 May 2021.